Showing results (1011-1020 of 2,413) with videos related to
Sort By:
Pageof 242
Journal of Medical Economics|October 16, 2019
Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozinJuan José Gorgojo-Martínez, Samuel J P Malkin, Virginia Martín, et al.Journal of Medical Economics|June 28, 2017
Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United StatesB Hunt, C C McConnachie, C Gamble, et al.Journal of Medical Economics|April 19, 2023
Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in JapanWentao Tang, Keigo Hanada, Yoshiharu Motoo, et al.Journal of Medical Economics|April 3, 2023
Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation studyTadao Ishida, Mayuko Nakakoji, Tatsunori Murata, et al.Journal of Medical Economics|April 22, 2023
Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertensionEros Papademetriou, Xing Liu, Amélie Beaudet, et al.Journal of Medical Economics|March 29, 2023
The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The NetherlandsAlexander V van Schoonhoven, Marcel H Schöttler, Erik H Serné, et al.Journal of Medical Economics|March 20, 2015
Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcersJ Bradford Rice, Urvi Desai, Ljubica Ristovska, et al.Journal of Medical Economics|March 20, 2015
Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in PortugalPedro A Laires, Flavia Ejzykowicz, Tun-Ying Hsu, et al.Journal of Medical Economics|August 12, 2020
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspectiveBoon Piang Cher, Kar Yee Gan, Mohamed Ismail Abdul Aziz, et al.Journal of Medical Economics|April 5, 2021
Real-world assessment of "OFF" episode-related healthcare resource utilization among patients with Parkinson's disease in the United StatesAndrew Thach, Eddie Jones, Eric Pappert, et al.Pageof 242